Cancer Screening Flashcards
Number 1 Cancer in Males
Prostate
Number 1 Cancer in Females
Breast
Number 1 Cancer that Males & Females Die from Each Year
Lung & bronchus
General Cancer Prevention
Avoid tobacco Be physically active Maintain a healthy weight Limit alcohol Avoid excess sun Eat a diet rich in fruits, veggies, & whole grains & low in sat/trans fats Protect against STIs Regular screening for breast, cervical, & colorectal cancer
Principles of Screening
Disease has high prevalence
Disease has serious consequences
Detectable pre-clinical phase
Treatment for pre-symptomatic disease more effective than after symptoms develop
Positive impact on clinical health outcomes
Other Considerations for General Screening
What are patient’s co-morbid conditions?
Associated life expectancy, feasibility of treatment, effects of treatment on QOL?
What will you do with the results?
Which cancers are largely asymptomatic in the early stages?
Colorectal
Breast
Cervical
What is the leading cause of death from gynecologic malignancy in the U.S.?
Ovarian cancer
Pelvic Examination in Ovarian Cancer
No evidence they reduce mortality
Early stage tumors rarely found
Usually detected at an advanced stage & associated with a poor prognosis
Screening for Ovarian Cancer
CA 125 & TVUS
Family ovarian cancer syndrome or BRCA genes: CA 125 & TVUS
Initiation at 35 years or 5-10 years earlier than earliest age of first diagnosis
BRCA1 Carriers & Breast, Ovarian, & Contralateral Breast Cancer Risk
Breast risk: 60%
Ovarian risk: 59%
Contralateral breast risk: 83%
BRCA2 Carriers & Breast, Ovarian, & Contralateral Breast Cancer Risk
Breast risk: 55%
Ovarian risk: 16.5%
Contralateral breast risk: 62%
When to Test for BRCA for Non-Ashkenazi Jewish Women
2 1st-degree relatives with breast cancer, one
When to Test for BRCA for Women of Ashkenazi Jewish Descent
1st degree relative with breast or ovarian CA
Positive Impact on Clinical Health Outcomes for Ovarian Cancer
Annual pelvic, CA-125, and TVUS DO NOT decrease mortality from ovarian cancer
Prevention of Ovarian Cancer
Oral contraceptives
Gynecologic surgery: tubal, hysterectomy
Pregnancy
Breastfeeding
Cervical Cancer Prevention
Pap test
Death rate decreased 50% since pap administration
Cervical Cancer Screening Recommendations
Women should begin screening at age 21 unless HIV or immunocompromised
21-29 cytology every 3 years
30 years old: cytology every 3 years, co-testing cytology & HPV testing every 5
May stop after 65 if adequate screening in past 10 years with 2 negative screens
High Risk Groups for Cervical Cancer
Patients with HIV infection
Patients who are immunosuppressed
Those who had in utero DES exposure
Women who have been treated for CIN2, CIN3, or cervical cancer
Cervical Cancer: Hysterectomy Patients who Still Need Pap Smears
Surgery was done as treatment for cervical CA or pre-cancer
Hysterectomy without removal of the cervix
Cervical Cancer Prevention
Gardasil
Avoid exposure to HPV
Don’t smoke
Pap smear
Epidemiology of Breast Cancer
Most common in U.S
Second leading cause of cancer death in women
Diagnosed as a result of abnormal screening study
Primary Risk Factors for Breast Cancer
Predominantly in females
Age: 85% age 50+
Screening Tools for Breast Cancer
Mammography
Ultrasound
MRI: high risk patients
Proper Clinical Breast Exam (CBE) Technique
Flatten breast tissue against chest
Examine in vertical strips
Make circular motions with pads of the middle 3 fingers
Examine each breast with 3 different pressure for at least 3 minutes
Epidemiology of Colorectal Cancer
3 most common cancer in U.S.
2nd leading cause of cancer-related deaths in U.S.
Assess Colorectal Cancer Risk
Start at age 20 & every 5 year thereafter
Have you ever had colorectal cancers or an adenomatous polyp?
Have you had inflammatory bowel disease?
Have any family members had CBC or adenomatous polyp? If so, how many were 1st degree relatives & at what age was cancer or polyp diagnosed?
Recommendations
Fecal occult blood test: begin at 50
Flexible sigmoidoscopy: begin at 50, every 5 years; + sensitive FOBT every 3 years
Colonoscopy: begin at 50, every 10 years
Virtual colonoscopy: every 5 years
FOBT
Finds blood in the stool (3 samples) Stool guaiac Immunochemical stool tests Check for some intestinal conditions or colorectal cancer \+ test = colonoscopy
Sigmoidoscopy
View rectum, sigmoid, and last 2 feet of large intestine
Biopsies can be taken
Risks of Sigmoidoscopy
Bleeding from site where biopsy was taken
Tear in colon or rectum wall
Drawbacks of Sigmoidoscopy
Cannot see entire colon
Proximal lesions may not be seen
Define Colonoscopy
Endoscopic exam of the colon AND the distal part of the small bowel with a fiber optic camera on a flexible tube passed through the rectum
Positives of a Colonoscopy
Visual diagnosis
Opportunity for biopsy or removal of lesions
Complications of Colonoscopy
Bleeding from biopsy site
Tear in the colon or rectum wall
CDC Colorectal Cancer Control Program
Colorectal CA screening services to low-income men & women aged 50-64
Program sites also provide diagnostic follow-up
Screening for High Risk Populations
Family history
Family adenomatous polyposis (FAP)
Hereditary non-polyposis colon cancer (HNPCC)
Screening for High Risk Populations: History of Adenomatous Polyps
Colonoscopy age 40 or 10 years prior to earliest diagnosis; repeat every 5 years
Based on pathology & # of adenomas
Adenoma with high grade dysplasia- repeat in 3 years
1-2 small tubular adenomas with low grade dysplasia- repeat in 5 years
Screening for High Risk Populations: Family Adenomatous Polyposis
Sigmoidoscopy starting at age 10-12
Screening for High Risk Populations: Hereditary Non-Polyposis Colon Cancer
Colonoscopy q1-2 years beginning at age 20-25 or 10 years prior to earliest CA diagnosis in family
Virtual Colonoscopy
Uses a CT scanner to take images of the entire bowel
2D & 3D
PROs of Virtual Colonoscopy
Doesn’t require sedation
Non-invasive
Entire bowel can be examined
CONs of Virtual Colonoscopy
Abnormality will need colonoscopy
Epidemiology of Prostate Cancer
Most common cancer in men
Mainly in older men
2nd leading cause of cancer death in U.S. men
Screening Tests for Prostate Cancer
DRE
PSA
DRE Testing in Prostate Cancer
Can detect 85% of tumors
Doesn’t show reduction in morbidity or mortality
PSA Screening Prostate CA
Give men the pros & cons and let them make their own screening diagnosis
Potential Benefits of Prostate Cancer Screening
Detect cancers early
Treatment more effective when it is found early
5-year survival with localized cancer 100%
Potential Risks of Prostate Cancer Screening
False positive test results lead to further tests
Potential SE: infection from biopsies
Treatment may have never affected a man’s health if left untreated
Complications of Prostate Cancer Treatment
Sexual dysfunction
Urinary incontinence
Bowel dysfunction
Screening in Regular Risk Men
Age 50 unless life expectancy
Screening in High Risk Men
Age 40
African American men
Family history of prostate CA esp.
Screening Guidelines for Lung Cancer for People at High Risk
55-74 years old
Fairly good health
At least 30 pack year history, still smoking, having quit last 15 years
Recommend Screening for Lung Cancer
Method: LDCT scan
Location: center that can accurately do scans; expertise to interpret & advise the patient
Risk: unnecessary biopsies, partial removal of lung
Principles of Lung Cancer Screening
Disease has high prevalence Disease has serious consequences Detectable preclinical phase Treatment for pre-symptomatic disease more effective than after symptoms develop Screening reduces cancer mortality
High Prevalence of Lung Cancer
2nd most common cancer in the US
Serious Consequences of Lung Cancer
1 cause of cancer mortality
Prevention of Lung Cancer
Smoking cessation
Prevention of Skin Cancer
Wear sunscreen
Don’t use tanning beds
Factors that Effectiveness Depends on for Skin Cancer
Whether clinician can identify early stage disease
Whether pathologist can accurately diagnose & histologically stage disease
Whether tumor is identified at a stage where treatment would be effective
Whether tumor identified by screening would become clinically meaningful
Epidemiology of Oral Cancers
Men > Women
Oropharyngeal CA linked with HPV